explore -WSS

explore

author：fashion 2025-10-02 00:35:34 - browse：93946

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： American TikTok star stuck in Dubai for months following rental car altercation

entertainment

WSS

Many immigrants are left out of maternal health programs

Anavex keeps shifting the goalposts in its clinical trials

Maui's cultural, historic landmarks damaged in the devastating wildfires

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

'Weather

South Korea throws huge K

knowledge

explore

hotspot

Bright Health sells Medicare Advantage business to Molina

The best solution to the drug shortages problem

Cancer drug shortages should be causing more outrage

Friends ask where James Watson's attitudes about race came from

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

'Weather

The high cost of giving birth even with insurance

Doctors increasingly discourage vaping amid mounting health concerns

As demand for Covid shots wanes, Moderna seeks its next success

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

focus

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

A biotech analyst on neuroscience, placebo effect, not over

Snowpack in the West is melting rapidly. Where will all that extra water go?

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

What AstraZeneca

Maui's cultural, historic landmarks damaged in the devastating wildfires

entertainment

entertainment

leisure time

knowledge